Thousands of cancer patients reach for biotin supplements hoping to restore hair lost during chemotherapy, but oncologists are raising alarms about a hidden danger: the vitamin can corrupt critical blood work that monitors for cancer recurrence.
Biotin, also called vitamin B7, has become a go-to remedy among patients seeking to rebuild their appearance after treatment. The supplement is cheap, available everywhere, and widely promoted online for stronger hair and nails. What many patients don't realize is that biotin interferes with the lab tests used to track some of the most common cancers, potentially masking dangerous signs that tumors are returning.
"People have the misconception that biotin supplements are harmless and there's no reason not to take them," said Dr. Brittany Dulmage, an oncodermatologist at Ohio State University's Comprehensive Cancer Center. "The reality is that the supplements may cause inaccurate lab results, resulting in a delay or change in patients' treatment plans."
The problem runs deeper than most patients understand. Biotin doesn't actually change hormone levels in the body, but it interferes with how those levels are measured. For prostate specific antigen and thyroid stimulating hormone tests, biotin can artificially lower readings, potentially hiding cancer recurrence in survivors. For reproductive hormones like estrogen and testosterone, it can falsely inflate results, delaying necessary therapy.
Dulmage, who leads the Oncodermatology Clinic at Ohio State, said more than half her patients with hair loss complications arrived on supplements they started themselves, often after stumbling on information online or hearing about it from friends.
Anna Malagoli, a breast cancer survivor from Columbus, discovered the risk the hard way. After her cancer entered remission, she began taking biotin to restore her long curly hair. "The amount of information on the Internet can lead you in different directions. I was taking so much biotin it's not even funny," she said. "Nobody mentioned one word that biotin vitamins or minerals or supplements could interfere with your treatment or your testing."
Malagoli's lab results became inconsistent. Numbers didn't align with how she felt physically. When she consulted with Dulmage, the explanation clicked: her biotin use was distorting the tests.
The interference affects tests for breast, prostate, thyroid, and ovarian cancers. Some of these tests rely on chemical reactions that involve biotin, so supplementation skews the results in unpredictable directions. Dulmage recently published research in JCO Oncology Practice urging oncologists to have frank conversations with patients about hair loss and warn them about biotin's testing interference.
For patients who refuse to stop biotin, Dulmage suggests pausing supplements at least 72 hours before blood work. But that strategy has a critical flaw: much blood work isn't scheduled in advance. Emergency cardiac tests for troponin, a heart attack marker, can't be delayed for biotin withdrawal. Patients won't know they're having a heart attack days in advance to stop the vitamin.
True biotin deficiency is exceedingly rare because the vitamin appears naturally in fruits, vegetables, meats, eggs, and dairy. Dulmage argues that most patients chasing biotin for hair recovery don't need it at all.
Instead, she recommends minoxidil, an FDA-approved over-the-counter treatment available as lotions and foams. It's proven safe and effective for most people, with the exception of those who are pregnant or breastfeeding. Malagoli tried both approaches and found minoxidil delivered better long-term results for her hair recovery.
"I don't know if my body just doesn't assimilate the supplements as well, but minoxidil is definitely more effective," she said. For patients wanting additional options, seeing a dermatologist can unlock other treatments tailored to individual needs.
Dulmage's research team documented their concerns after noticing a troubling pattern in the clinic: cancer survivors self-treating with biotin, unaware that the same supplement they thought was harmless could delay detection of their cancer's return. The oversight highlights a gap in patient education during and after cancer care.
Author Jessica Williams: "Cancer patients deserve straightforward talk about what actually works for hair loss and what doesn't, especially when the wrong choice could mask a tumor's comeback."
Comments